Despite the lack of punctual data on long-term immunogenicity and efficacy, based on severe outcomes of Morbillivirus infection and safety and immunogenicity data from cohort studies and randomized trials, the measles vaccine is recommended by HIV guidelines in PWH with CD4+ count >200 cells/mm3 and on stable ART [102,104]. Here, CD4 is linked to measles.